Health 2.0 Europe 2016

11 - 12 May 2016, Barcelona, Spain.
The 7th edition of Health 2.0 Europe is coming back to Barcelona for 3 full days of content that will explore European and international innovation in patient-provider communication, consumer health, data analytics and more.

Over 120 speakers and 600 attendees from around the world will reconvene to experience over 50 live product demos of innovative solutions that will shake up European health systems.

Confirmed keynotes already include:

  • Esther Dyson, Chairman, EDventure Holdings (USA)
  • Dr. Rafael Grossmann, Practicing surgeon and digital health pionneer (USA)
  • Damien Marmion, Global Head of Health, AXA (France)
  • Dr. Julio Mayol, Director of Innovation, Hospital Clinico San Carlos (Spain)
  • Pēteris Zilgalvis, Head of Unit, eHealth and Well Being – DG CONNECT, European Commission (Belgium)

Confirmed digital health champions also include:

  • Artem Andrianov, CEO, Cyntegrity (Germany)
  • Jani Ahonala, Co-founder & Chairman of the Board, Noona Healthcare, (Finland)
  • Dr. Tom Albert, Director - Health Strategy, AXA Krankenversicherung AG (Germany)
  • Jordina Arcal, Co-founder & COO, HealthApp (Spain)
  • Dr. Alexander Börve, Founder and CEO, FirstDerm.com (Sweden/USA)
  • Vas Bailey, Principal, Quid, Inc (USA)
  • Vedran Boškić, Healthcare ICT consultant, Parsek (Slovenia)
  • Joan Cornet, mHealth Director, Mobile World Capital (Spain)
  • Dustin DiTommaso, SVP, Behavior Change Design, Mad*Pow (USA)
  • Dr. Eduardo García Cruz, Urologist and Men’s Health Specialist, Barcelona Hospital Clinic (Spain)
  • Jorge Gonzalez, Managing Director, TICBioMed (Spain)
  • Jamison Feramisco, President and Co-Founder, Transfuse Solutions, Inc. (USA)
  • Tal Givoly, CEO and Co-founder, Medivizor (Israel)
  • Jorge Gonzalez Olalla, Managing Director, TICBioMed (Spain)
  • Min-Sung Sean Kim, Partner, XL Health (Germany)
  • Jörg Land, CEO, Tinnitracks (Germany)
  • Robert Milnes, CEO, Fertility Focus Limited (United Kingdom)
  • Peter Ohnemus, President & CEO, Dacadoo (Switzerland)
  • Pablo Pantaleoni, CEO, MedTep (Spain/USA)
  • Michael Seres, Founder, 11Health (United Kingdom)
  • Dr. Alexander Schachinger, CEO, EPatient RSD (Germany)
  • Mitchell Silva, Founder and CEO, Esperity (Belgium)
  • Marta Sjögren, Principal, Northzone (Sweden)
  • Pierre Socha, Investment Manager, Amadeus Capital Partners (United Kingdom)
  • Ed Stafford, Director of Informatics, Genomics England (United Kingdom)
  • Unity Stoakes, ‎Co-founder and President, StartUp Health (USA)
  • Donato Tramuto, President and CEO, Healthways and Founder, Health eVillages, (USA)
  • Salvador Vera, CEO, MYSPHERA (Spain)
  • Frank Westermann, Co-founder and CEO, mysugr (Austria)

A mix of visionary keynotes and interactive panel discussions, the 2016 edition will cover some of the following overarching themes:

  • Building blocks to a dynamic health innovation ecosystem
  • Data analytics: Structuring information for decision making
  • Solutions for hospitals and health professionals
  • Gamification and design strategies for behaviour change
  • Pharma 2.0: Going beyond the pill
  • Who will pay for Health 2.0?
  • Reimbursement - Players, trends, criteria and processes
  • The rise of consumer health interfaces
  • "SHUSH topics" and the infamous Unmentionables
  • Health 2.0 applications in emerging markets

For further information and to register, please visit:
https://goo.gl/IVCb3P

PS: Get 15% discount to attend Health 2.0 Europe 2016 using the code EHNEWS16

About Health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, developer competitions, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care. In addition to our flagship event held in the Bay Area each Fall, we host events around the world including in Europe, Latin America and India, and new for 2015 Korea and Japan.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...